Concert Pharmaceuticals Inc.

September 23, 2015November 5, 2015

Concert Pharma Reports Phase 1 Results of Experimental CF Therapy CTP-656

Cystic Fibrosis, News

Concert Pharma, a biotechnology company utilizing deuterium chemistry to discover and develop innovative drug products that can address unmet medical needs, recently announced positive results from its Phase 1 single ascending dose study ... Read more

March 18, 2015November 5, 2015

Concert Pharma Starts Phase 1 Trial on Deuterated Ivacaftor for CF

Cystic Fibrosis, News

Clinical stage Concert Pharmaceuticals Inc. has initiated a phase 1 clinical study to evaluate a deuterium-modified version of ivacaftor, as a potential therapy for cystic fibrosis (CF). The company is planning on studying ... Read more